Valuable Funding for Biomaterials Company
A company whose synthetic bone-graft implants demonstrate world-beating performance will complete regulatory clearance and market…read more
Orthogem Ltd is a biomaterials company who have developed a new generation of synthetic bone graft substitute. The platform technology called Tripore consists of granules of hydroxyapatite (material which makes up natural bone) containing pores in a range of three sizes, meaning it is uniquely fully resorbable i.e. replaced by natural bone. The product and production process are patent protected, extending worldwide, allowing the company to develop a range of product extensions for use in a variety of clinical scenarios.
Associated Fund Early Advantage Fund
Sector Medical / Biotechnology